upadacitinib vs Zemprocitinib

Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.

Atopic Dermatitis

Shared mechanism: JAK1 · full Atopic Dermatitis pipeline

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Atopic DermatitisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT03607422 · Phase 3 · completed

Participants were randomized and the trial was quadruple-blinded and placebo-controlled in 912 adolescents and adults. Both co-primary endpoints -- a 75% reduction in the validated Eczema Area and Severity Index (EASI75) and clearance or near-clearance on the validated Investigator Global Assessment -- were clearly met for both upadacitinib doses versus placebo at week 16 (p<0.001 for all comparisons).

Next expected readout: November 2026 · NCT06389136 (registry estimate)

Reported efficacy

Main Study: Percentage of Participants Achieving at Least a 75% Reduction in Eczema Area and Severity Index Score (EASI 75) From Baseline at Week 16 (Baseline and Week 16); Main Study: Percentage of Participants Achieving Validated Investigator Global Assessment for Atopic Dermatitis (vIGA-AD) of 0 or 1 With a Reduction From Baseline of ≥ 2 Points at Week 16 (Baseline and Week 16): EASI-75 response at week 16 (Measure Up 2): 60.1% (upadacitinib 15 mg) vs 72.9% (upadacitinib 30 mg) vs 13.3% (placebo). (met)

Result source: NCT03607422

Zemprocitinib

Developed by Lynk Pharmaceuticals and partners

Phase 3 in Atopic Dermatitissmall molecule
Reliable signal

NCT06277245 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 356 patients that measured EASI-75 skin clearance and Investigator's Global Assessment response at week 16, the standard efficacy measures for atopic dermatitis. Both the 12 mg and 24 mg doses produced large, statistically significant improvements over placebo on both endpoints.

Caveat: this result is taken from a company announcement or a news report of one, not from the trial registry or a peer-reviewed publication. Treat the figures as the sponsor's own statement, not as independently verified evidence.

Reported efficacy

Eczema Area and Severity Index (EASI-75) at Week 16 (Baseline and Week 16); Investigator's Global Assessment (IGA) score of 0/1 at Week 16 (Baseline and Week 16): EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) (met)

Result source: NCT06277245

Results for Atopic Dermatitis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointupadacitinibZemprocitinib
EASI-7560.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
—Not posted · NCT06277245
IGA 0/1 with 2-point improvement—Trial running · NCT03568318—Not posted · NCT06277245
EASI-9042.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
—Not posted · NCT06277245
EASI, % change-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
—Not posted · NCT06277245

EASI-75

upadacitinib
60.1% vs 13.3%+46.8 vs placebo15 mg QD · wk 16 · n 276NCT03607422
63 other results
  • 69.6% vs 16.3% 15 mg QD · wk 16 · n 281 · Phase 3 · primary NCT03569293
  • 72.9% vs 13.3% 30 mg QD · wk 16 · n 282 · Phase 3 · primary NCT03607422
  • 79.7% vs 16.3% 30 mg QD · wk 16 · n 285 · Phase 3 · primary NCT03569293
  • 72.4% vs 62.6% 30 mg QD · wk 16 · n 342 · Phase 3 · primary NCT03738397
  • 33% vs 3.6% 15 mg QD · wk 2 · n 276 · Phase 3 · secondary NCT03607422
  • 38.1% vs 3.6% 15 mg QD · wk 2 · n 281 · Phase 3 · secondary NCT03569293
  • 44% vs 3.6% 30 mg QD · wk 2 · n 282 · Phase 3 · secondary NCT03607422
  • 47.4% vs 3.6% 30 mg QD · wk 2 · n 285 · Phase 3 · secondary NCT03569293
  • 69% vs 13.3% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 74.6% vs 12.1% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 37.9% vs 6.7% 15 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03607422
  • 39.7% vs 3.4% 15 mg QD · wk 2 · n 63 · Phase 3 · secondary NCT03569293
  • 73.4% vs 13.3% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 84.5% vs 12.1% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 53.2% vs 6.7% 30 mg QD · wk 2 · n 62 · Phase 3 · secondary NCT03607422
  • 55.8% vs 3.4% 30 mg QD · wk 2 · n 58 · Phase 3 · secondary NCT03569293
  • 44.3% vs 18.2% 30 mg QD · wk 2 · n 342 · Phase 3 · secondary NCT03738397
  • 52.4% vs 9.8% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 52.4% vs 7.3% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 69% vs 9.8% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 81% vs 7.3% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 28.6% vs 9.8% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 31% vs 7.3% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 88 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 76 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 64 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 52 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 40 · n 7 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 15 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 32 · n 7 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 15 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 7 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 15 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 15 mg · wk 20 · n 7 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 15 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 88 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 76 · n 4 · Phase 2 · secondary NCT02925117
  • 80% vs 100% 30 mg · wk 64 · n 8 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 64 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 52 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 52 · n 4 · Phase 2 · secondary NCT02925117
  • 66.7% vs 100% 30 mg · wk 40 · n 8 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 30 mg · wk 40 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 40 · n 4 · Phase 2 · secondary NCT02925117
  • 100% vs 100% 30 mg · wk 32 · n 8 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 5 · Phase 2 · secondary NCT02925117
  • 50% vs 100% 30 mg · wk 32 · n 4 · Phase 2 · secondary NCT02925117
  • 85.7% vs 100% 30 mg · wk 24 · n 8 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 5 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 30 mg · wk 24 · n 4 · Phase 2 · secondary NCT02925117
  • 12.5% vs 11.1% 30 mg · wk 20 · n 8 · Phase 2 · secondary NCT02925117
  • 20% vs 11.1% 30 mg · wk 20 · n 5 · Phase 2 · secondary NCT02925117
  • 25% vs 11.1% 30 mg · wk 20 · n 4 · Phase 2 · secondary NCT02925117
  • 0% vs 100% 7.5 mg · wk 32 · n 11 · Phase 2 · secondary NCT02925117
  • 33.3% vs 100% 7.5 mg · wk 24 · n 11 · Phase 2 · secondary NCT02925117
  • 0% vs 11.1% 7.5 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 9.1% vs 11.1% 7.5 mg · wk 20 · n 11 · Phase 2 · secondary NCT02925117
Zemprocitinib
—Not posted · NCT06277245

IGA 0/1 with 2-point improvement

upadacitinib
—Trial running · NCT03568318
Zemprocitinib
—Not posted · NCT06277245

EASI-90

upadacitinib
42.4% vs 5.4%+37 vs placebo15 mg QD · wk 16 · n 276NCT03607422
14 other results
  • 53.1% vs 8.1% 15 mg QD · wk 16 · n 281 · Phase 3 · secondary NCT03569293
  • 58.5% vs 5.4% 30 mg QD · wk 16 · n 282 · Phase 3 · secondary NCT03607422
  • 65.8% vs 8.1% 30 mg QD · wk 16 · n 285 · Phase 3 · secondary NCT03569293
  • 48.3% vs 1.7% 15 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03607422
  • 47.6% vs 3.4% 15 mg QD · wk 16 · n 63 · Phase 3 · secondary NCT03569293
  • 62% vs 1.7% 30 mg QD · wk 16 · n 62 · Phase 3 · secondary NCT03607422
  • 74.1% vs 3.4% 30 mg QD · wk 16 · n 58 · Phase 3 · secondary NCT03569293
  • 61.6% vs 40.3% 30 mg QD · wk 16 · n 342 · Phase 3 · secondary NCT03738397
  • 26.2% vs 2.4% 15 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 26.2% vs 0% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 50% vs 2.4% 30 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 45.2% vs 0% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 14.3% vs 2.4% 7.5 mg · wk 16 · n 42 · Phase 2 · secondary NCT02925117
  • 9.5% vs 0% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
Zemprocitinib
—Not posted · NCT06277245

EASI, % change

upadacitinib
-74.1% vs -34.5%−39.6 vs placebo15 mg QD · wk 16 · n 246NCT03607422
69 other results
  • -80.2% vs -40.7% 15 mg QD · wk 16 · n 244 · Phase 3 · secondary NCT03569293
  • -84.7% vs -34.5% 30 mg QD · wk 16 · n 250 · Phase 3 · secondary NCT03607422
  • -87.7% vs -40.7% 30 mg QD · wk 16 · n 259 · Phase 3 · secondary NCT03569293
  • -77.8% vs -42.2% 15 mg QD · wk 16 · n 53 · Phase 3 · secondary NCT03607422
  • -82.1% vs -43.5% 15 mg QD · wk 16 · n 59 · Phase 3 · secondary NCT03569293
  • -84.8% vs -42.2% 30 mg QD · wk 16 · n 52 · Phase 3 · secondary NCT03607422
  • -89.4% vs -43.5% 30 mg QD · wk 16 · n 57 · Phase 3 · secondary NCT03569293
  • -61.7% vs -23% 15 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -74.4% vs -23% 30 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • -39.4% vs -23% 7.5 mg · wk 16 · n 42 · Phase 2 · primary NCT02925117
  • 617.5% vs -37.7% 15 mg · wk 88 · n 17 · Phase 2 · secondary NCT02925117
  • 99.3% vs -37.7% 15 mg · wk 88 · n 18 · Phase 2 · secondary NCT02925117
  • 614% vs -37.3% 15 mg · wk 76 · n 17 · Phase 2 · secondary NCT02925117
  • 130.2% vs -37.3% 15 mg · wk 76 · n 18 · Phase 2 · secondary NCT02925117
  • 614.6% vs -35.8% 15 mg · wk 64 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -35.8% 15 mg · wk 64 · n 18 · Phase 2 · secondary NCT02925117
  • 613.8% vs -29.8% 15 mg · wk 52 · n 17 · Phase 2 · secondary NCT02925117
  • 104.1% vs -29.8% 15 mg · wk 52 · n 18 · Phase 2 · secondary NCT02925117
  • 608.8% vs -31.2% 15 mg · wk 40 · n 17 · Phase 2 · secondary NCT02925117
  • 154.1% vs -31.2% 15 mg · wk 40 · n 18 · Phase 2 · secondary NCT02925117
  • 613.3% vs -2.3% 15 mg · wk 32 · n 17 · Phase 2 · secondary NCT02925117
  • 151.7% vs -2.3% 15 mg · wk 32 · n 18 · Phase 2 · secondary NCT02925117
  • 607.3% vs 13.5% 15 mg · wk 24 · n 17 · Phase 2 · secondary NCT02925117
  • 72.6% vs 13.5% 15 mg · wk 24 · n 18 · Phase 2 · secondary NCT02925117
  • 582.3% vs 50.7% 15 mg · wk 20 · n 17 · Phase 2 · secondary NCT02925117
  • 65.7% vs 50.7% 15 mg · wk 20 · n 18 · Phase 2 · secondary NCT02925117
  • -65.4% vs -17.5% 15 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -84.6% vs -37.7% 30 mg · wk 88 · n 10 · Phase 2 · secondary NCT02925117
  • 769.7% vs -37.7% 30 mg · wk 88 · n 14 · Phase 2 · secondary NCT02925117
  • 39% vs -37.7% 30 mg · wk 88 · n 19 · Phase 2 · secondary NCT02925117
  • -90.3% vs -37.3% 30 mg · wk 76 · n 10 · Phase 2 · secondary NCT02925117
  • 787.8% vs -37.3% 30 mg · wk 76 · n 14 · Phase 2 · secondary NCT02925117
  • 24.4% vs -37.3% 30 mg · wk 76 · n 19 · Phase 2 · secondary NCT02925117
  • -91.4% vs -35.8% 30 mg · wk 64 · n 10 · Phase 2 · secondary NCT02925117
  • 802.1% vs -35.8% 30 mg · wk 64 · n 14 · Phase 2 · secondary NCT02925117
  • 63.6% vs -35.8% 30 mg · wk 64 · n 19 · Phase 2 · secondary NCT02925117
  • -90.1% vs -29.8% 30 mg · wk 52 · n 10 · Phase 2 · secondary NCT02925117
  • 799.5% vs -29.8% 30 mg · wk 52 · n 14 · Phase 2 · secondary NCT02925117
  • -13.3% vs -29.8% 30 mg · wk 52 · n 19 · Phase 2 · secondary NCT02925117
  • -92% vs -31.2% 30 mg · wk 40 · n 10 · Phase 2 · secondary NCT02925117
  • 778.9% vs -31.2% 30 mg · wk 40 · n 14 · Phase 2 · secondary NCT02925117
  • 140.6% vs -31.2% 30 mg · wk 40 · n 19 · Phase 2 · secondary NCT02925117
  • -69.6% vs 13.5% 30 mg · wk 24 · n 19 · Phase 2 · secondary NCT02925117
  • -73.8% vs 50.7% 30 mg · wk 20 · n 19 · Phase 2 · secondary NCT02925117
  • -82.8% vs -17.5% 30 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • -83.1% vs -2.3% 30 mg · wk 32 · n 10 · Phase 2 · secondary NCT02925117
  • 771.5% vs -2.3% 30 mg · wk 32 · n 14 · Phase 2 · secondary NCT02925117
  • -28.8% vs -2.3% 30 mg · wk 32 · n 19 · Phase 2 · secondary NCT02925117
  • -67.5% vs 13.5% 30 mg · wk 24 · n 10 · Phase 2 · secondary NCT02925117
  • 898.5% vs 13.5% 30 mg · wk 24 · n 14 · Phase 2 · secondary NCT02925117
  • 181.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 63.5% vs -2.3% 7.5 mg · wk 32 · n 15 · Phase 2 · secondary NCT02925117
  • 189.6% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 59% vs 13.5% 7.5 mg · wk 24 · n 15 · Phase 2 · secondary NCT02925117
  • 186% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • 79.1% vs 50.7% 7.5 mg · wk 20 · n 15 · Phase 2 · secondary NCT02925117
  • -43.7% vs -17.5% 7.5 mg · wk 8 · n 42 · Phase 2 · secondary NCT02925117
  • 11.8% vs 50.7% 30 mg · wk 20 · n 10 · Phase 2 · secondary NCT02925117
  • 791.5% vs 50.7% 30 mg · wk 20 · n 14 · Phase 2 · secondary NCT02925117
  • 170.7% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 69.1% vs -37.7% 7.5 mg · wk 88 · n 15 · Phase 2 · secondary NCT02925117
  • 201.4% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 77.7% vs -37.3% 7.5 mg · wk 76 · n 15 · Phase 2 · secondary NCT02925117
  • 179.9% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 71.8% vs -35.8% 7.5 mg · wk 64 · n 15 · Phase 2 · secondary NCT02925117
  • 189.1% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 74.4% vs -29.8% 7.5 mg · wk 52 · n 15 · Phase 2 · secondary NCT02925117
  • 200.9% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
  • 77.6% vs -31.2% 7.5 mg · wk 40 · n 15 · Phase 2 · secondary NCT02925117
Zemprocitinib
—Not posted · NCT06277245
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Reviewed results are available, but are not yet structured for this comparison. These sourced summaries are shown separately from the aligned rows.

Zemprocitinib
EASI-75 at Week 16: +38.1 percentage points (12 mg) and +46.4 percentage points (24 mg) vs placebo (p<0.0001); IGA 0/1 response: +30.3 percentage points (12 mg) and +31.0 percentage points (24 mg) vs placebo (p<0.0001) NCT06277245 · Phase 3 · design grade: strong · publication or press release

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. upadacitinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricupadacitinib
Dropout rate
—15 mga
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
5.2%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
4.1%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
3.2%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
4.5%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
3.3%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
4.9%30 mg QD
NCT03569293 · Phase 3
5.2%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
2.6%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
10.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
16.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
8.8%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.9%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—15 mga
NCT03607422 · Phase 3
show 48 more results
—15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
—15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
—30 mg
NCT03607422 · Phase 3
0.4%30 mg QD
NCT03607422 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg QD
NCT03569293 · Phase 3
0%15 mg QD
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
—15 mg
NCT03569293 · Phase 3
0.4%15 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
—30 mg
NCT03569293 · Phase 3
1.6%30 mg QD
NCT03569293 · Phase 3
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
—30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.7%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
2%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
7.1%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Serious AEs
15.4%15 mga
NCT03607422 · Phase 3
show 48 more results
10.9%15 mg
NCT03607422 · Phase 3
3.4%15 mg QD
NCT03607422 · Phase 3
10.6%15 mg
NCT03607422 · Phase 3
16.6%15 mg
NCT03607422 · Phase 3
1.2%15 mg QD
NCT03607422 · Phase 3
13.8%30 mg
NCT03607422 · Phase 3
16.9%30 mg
NCT03607422 · Phase 3
0%30 mg QD
NCT03607422 · Phase 3
17.3%30 mg
NCT03607422 · Phase 3
17.4%30 mg
NCT03607422 · Phase 3
2.8%30 mg QD
NCT03607422 · Phase 3
3.3%15 mg
NCT03569293 · Phase 3
12.5%15 mg QD
NCT03569293 · Phase 3
3.1%15 mg QD
NCT03569293 · Phase 3
14.7%15 mg
NCT03569293 · Phase 3
14.3%15 mg
NCT03569293 · Phase 3
2.1%15 mg QD
NCT03569293 · Phase 3
22.2%30 mg
NCT03569293 · Phase 3
10.9%30 mg QD
NCT03569293 · Phase 3
0%30 mg QD
NCT03569293 · Phase 3
20%30 mg
NCT03569293 · Phase 3
18.4%30 mg
NCT03569293 · Phase 3
3.3%30 mg QD
NCT03569293 · Phase 3
3.5%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
1.4%15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.7%15 mg then 30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0.8%30 mg then 15 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
0%30 mg
NCT05507580 · Phase 4 · registry result, not featured evidence
5.9%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
5.5%30 mg
NCT04195698 · Phase 3 · registry result, not featured evidence
4.1%30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
2.4%15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
6.1%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0%30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
4.8%7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
—7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
15 mga
covid-19 23.1% (placebo 0%)
acne 19.2% (placebo 3.3%)
dermatitis atopic 19.2% (placebo 13.3%)
NCT03607422 · Phase 3
show 38 more results
15 mg
covid-19 27.3% (placebo 0%)
upper respiratory tract infection 21.8% (placebo 1.7%)
acne 18.2% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg QD
acne 10.3% (placebo 3.3%)
upper respiratory tract infection 10.3% (placebo 1.7%)
oropharyngeal pain 6.9% (placebo 0%)
NCT03607422 · Phase 3
15 mg
covid-19 31.7% (placebo 0%)
acne 19.2% (placebo 3.3%)
blood creatine phosphokinase increased 17.3% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg
covid-19 31.9% (placebo 0%)
dermatitis atopic 17.9% (placebo 13.3%)
upper respiratory tract infection 14.4% (placebo 1.7%)
NCT03607422 · Phase 3
15 mg QD
acne 12.8% (placebo 3.3%)
headache 7% (placebo 3.3%)
nasopharyngitis 6.2% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 41.4% (placebo 0%)
acne 34.5% (placebo 3.3%)
dermatitis atopic 24.1% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 32.2% (placebo 0%)
blood creatine phosphokinase increased 18.6% (placebo 1.7%)
acne 11.9% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg QD
acne 14.5% (placebo 3.3%)
blood creatine phosphokinase increased 9.7% (placebo 1.7%)
headache 8.1% (placebo 3.3%)
NCT03607422 · Phase 3
30 mg
covid-19 39.4% (placebo 0%)
acne 25% (placebo 3.3%)
dermatitis atopic 15.4% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg
covid-19 29.8% (placebo 0%)
blood creatine phosphokinase increased 18.3% (placebo 1.7%)
dermatitis atopic 14.9% (placebo 13.3%)
NCT03607422 · Phase 3
30 mg QD
acne 15% (placebo 3.3%)
nasopharyngitis 8.1% (placebo 3.3%)
headache 6.5% (placebo 3.3%)
NCT03607422 · Phase 3
15 mg
covid-19 20% (placebo 0%)
acne 16.7% (placebo 1.6%)
blood creatine phosphokinase increased 16.7% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
covid-19 25% (placebo 0%)
upper respiratory tract infection 21.9% (placebo 8.2%)
blood creatine phosphokinase increased 12.5% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
acne 14.1% (placebo 1.6%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
headache 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg
covid-19 38.2% (placebo 0%)
dermatitis atopic 18.6% (placebo 3.3%)
upper respiratory tract infection 18.6% (placebo 8.2%)
NCT03569293 · Phase 3
15 mg
covid-19 28.6% (placebo 0%)
nasopharyngitis 16.5% (placebo 1.6%)
dermatitis atopic 16% (placebo 3.3%)
NCT03569293 · Phase 3
15 mg QD
upper respiratory tract infection 9.6% (placebo 8.2%)
nasopharyngitis 7.9% (placebo 1.6%)
acne 5.4% (placebo 1.6%)
NCT03569293 · Phase 3
30 mg
acne 37% (placebo 1.6%)
upper respiratory tract infection 33.3% (placebo 8.2%)
dermatitis atopic 29.6% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
covid-19 35.9% (placebo 0%)
acne 28.1% (placebo 1.6%)
upper respiratory tract infection 28.1% (placebo 8.2%)
NCT03569293 · Phase 3
30 mg QD
acne 15.6% (placebo 1.6%)
upper respiratory tract infection 12.5% (placebo 8.2%)
blood creatine phosphokinase increased 7.8% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 38.1% (placebo 0%)
acne 22.9% (placebo 1.6%)
blood creatine phosphokinase increased 17.1% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg
covid-19 35.1% (placebo 0%)
acne 18.9% (placebo 1.6%)
dermatitis atopic 18% (placebo 3.3%)
NCT03569293 · Phase 3
30 mg QD
acne 16.5% (placebo 1.6%)
upper respiratory tract infection 12.8% (placebo 8.2%)
nasopharyngitis 11.5% (placebo 1.6%)
NCT03569293 · Phase 3
15 mg
acne 7%
nasopharyngitis 5.7%
upper respiratory tract infection 3.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg
nasopharyngitis 11.1%
dermatitis atopic 8.3%
upper respiratory tract infection 6.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
15 mg then 30 mg
dermatitis atopic 16%
nasopharyngitis 4.2%
acne 2.8%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 13.8%
nasopharyngitis 9.1%
dermatitis atopic 3.9%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg then 15 mg
dermatitis atopic 12%
nasopharyngitis 7.5%
acne 6%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
dermatitis atopic 16.5%
acne 6.6%
eczema 5.5%
NCT05507580 · Phase 4 · registry result, not featured evidence
30 mg
acne 20.5%
covid-19 13.4%
blood creatine phosphokinase increased 13%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg
acne 22.9%
dermatitis atopic 19.1%
blood creatine phosphokinase increased 14.8%
NCT04195698 · Phase 3 · registry result, not featured evidence
30 mg QD
acne 18.7%
dermatitis atopic 10.5%
blood creatine phosphokinase increased 7.6%
NCT03738397 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
nasopharyngitis 11.9% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
15 mg
upper respiratory tract infection 11.9% (placebo 5.4%)
nasopharyngitis 9.5% (placebo 1.1%)
blood creatine phosphokinase increased 7.1% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
upper respiratory tract infection 22.8% (placebo 5.4%)
dermatitis atopic 19.3% (placebo 2.2%)
acne 11.4% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
30 mg
acne 14.3% (placebo 1.1%)
upper respiratory tract infection 11.9% (placebo 5.4%)
blood creatine phosphokinase increased 9.5% (placebo 3.2%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 14.3% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence
7.5 mg
upper respiratory tract infection 16.7% (placebo 5.4%)
dermatitis atopic 11.9% (placebo 2.2%)
acne 9.5% (placebo 1.1%)
NCT02925117 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

upadacitinib

EASI-75 60.1% (n=276) vs 13.3% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 63 more results
33% (n=276) vs 3.6% (n=278) placebo @ 2wk15 mg QD
NCT03607422 · Phase 3
69% (n=58) vs 13.3% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
37.9% (n=58) vs 6.7% (n=60) placebo @ 2wk15 mg QD
NCT03607422 · Phase 3
69.6% (n=281) vs 16.3% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
38.1% (n=281) vs 3.6% (n=281) placebo @ 2wk15 mg QD
NCT03569293 · Phase 3
74.6% (n=63) vs 12.1% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
39.7% (n=63) vs 3.4% (n=58) placebo @ 2wk15 mg QD
NCT03569293 · Phase 3
52.4% (n=42) vs 9.8% (n=41) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
52.4% (n=42) vs 7.3% (n=41) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 11.1% (n=9) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 11.1% (n=9) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=8) vs 100% (n=9) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=8) vs 100% (n=9) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=7) vs 100% (n=9) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
72.9% (n=282) vs 13.3% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
44% (n=282) vs 3.6% (n=278) placebo @ 2wk30 mg QD
NCT03607422 · Phase 3
73.4% (n=62) vs 13.3% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
53.2% (n=62) vs 6.7% (n=60) placebo @ 2wk30 mg QD
NCT03607422 · Phase 3
79.7% (n=285) vs 16.3% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
47.4% (n=285) vs 3.6% (n=281) placebo @ 2wk30 mg QD
NCT03569293 · Phase 3
84.5% (n=58) vs 12.1% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
55.8% (n=58) vs 3.4% (n=58) placebo @ 2wk30 mg QD
NCT03569293 · Phase 3
72.4% (n=342) vs 62.6% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
44.3% (n=342) vs 18.2% (n=331) Dupilumab @ 2wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
69% (n=42) vs 9.8% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
81% (n=42) vs 7.3% (n=41) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
12.5% (n=8) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
20% (n=5) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
25% (n=4) vs 11.1% (n=9) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
85.7% (n=8) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=5) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=4) vs 100% (n=9) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=5) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
66.7% (n=8) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=5) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
66.7% (n=8) vs 100% (n=9) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=4) vs 100% (n=9) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
80% (n=8) vs 100% (n=9) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=8) vs 100% (n=9) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
100% (n=4) vs 100% (n=9) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
28.6% (n=42) vs 9.8% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
31% (n=42) vs 7.3% (n=41) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=10) vs 11.1% (n=9) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
9.1% (n=11) vs 11.1% (n=9) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
33.3% (n=11) vs 100% (n=9) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
0% (n=11) vs 100% (n=9) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
vIGA-AD 0 1 38.8% (n=276) vs 4.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
44.8% (n=58) vs 5% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
48.1% (n=281) vs 8.4% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
46% (n=63) vs 6.9% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
52% (n=282) vs 4.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
59.4% (n=62) vs 5% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=285) vs 8.4% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
70.7% (n=58) vs 6.9% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
Worst Itch NRS 4-Point Improvement 41.9% (n=270) vs 9.1% (n=274) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 38 more results
48.9% (n=270) vs 3.6% (n=274) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=270) vs 0.7% (n=274) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
7.4% (n=269) vs 0.7% (n=267) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
11.5% (n=269) vs 3% (n=267) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
38.2% (n=55) vs 3.4% (n=59) placebo @ 4wk15 mg QD
NCT03607422 · Phase 3
12.7% (n=55) vs 0% (n=59) placebo @ 1wk15 mg QD
NCT03607422 · Phase 3
8.9% (n=56) vs 0% (n=59) placebo @ 0.29wk15 mg QD
NCT03607422 · Phase 3
14.3% (n=56) vs 1.7% (n=59) placebo @ 0.43wk15 mg QD
NCT03607422 · Phase 3
52.2% (n=274) vs 11.8% (n=272) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
51.5% (n=274) vs 4.4% (n=272) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
15% (n=274) vs 0.4% (n=272) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
10.5% (n=275) vs 3.7% (n=270) placebo @ 0.29wk15 mg QD
NCT03569293 · Phase 3
16.4% (n=275) vs 3.3% (n=270) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 10.5% (n=57) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
49.2% (n=61) vs 3.5% (n=57) placebo @ 4wk15 mg QD
NCT03569293 · Phase 3
9.8% (n=61) vs 0% (n=57) placebo @ 1wk15 mg QD
NCT03569293 · Phase 3
16.9% (n=59) vs 5.4% (n=56) placebo @ 0.43wk15 mg QD
NCT03569293 · Phase 3
59.6% (n=280) vs 9.1% (n=274) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
60.7% (n=280) vs 3.6% (n=274) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
15.7% (n=280) vs 0.7% (n=274) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
7.9% (n=278) vs 0.7% (n=267) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
17.3% (n=278) vs 3% (n=267) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
56.7% (n=60) vs 3.4% (n=59) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
50% (n=60) vs 3.4% (n=59) placebo @ 4wk30 mg QD
NCT03607422 · Phase 3
5% (n=60) vs 0% (n=59) placebo @ 1wk30 mg QD
NCT03607422 · Phase 3
3.2% (n=62) vs 0% (n=59) placebo @ 0.29wk30 mg QD
NCT03607422 · Phase 3
9.7% (n=62) vs 1.7% (n=59) placebo @ 0.43wk30 mg QD
NCT03607422 · Phase 3
60% (n=280) vs 11.8% (n=272) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
66.8% (n=280) vs 4.4% (n=272) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
19.6% (n=280) vs 0.4% (n=272) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
11.8% (n=279) vs 3.7% (n=270) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
21.1% (n=279) vs 3.3% (n=270) placebo @ 0.43wk30 mg QD
NCT03569293 · Phase 3
58.9% (n=56) vs 10.5% (n=57) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
64.3% (n=56) vs 3.5% (n=57) placebo @ 4wk30 mg QD
NCT03569293 · Phase 3
23.2% (n=56) vs 0% (n=57) placebo @ 1wk30 mg QD
NCT03569293 · Phase 3
14% (n=57) vs 1.8% (n=56) placebo @ 0.29wk30 mg QD
NCT03569293 · Phase 3
56.1% (n=334) vs 36.4% (n=323) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
EASI-90 42.4% (n=276) vs 5.4% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 14 more results
48.3% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
53.1% (n=281) vs 8.1% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
47.6% (n=63) vs 3.4% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
26.2% (n=42) vs 0% (n=41) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
26.2% (n=42) vs 2.4% (n=41) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
58.5% (n=282) vs 5.4% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
62% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
65.8% (n=285) vs 8.1% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
74.1% (n=58) vs 3.4% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
61.6% (n=342) vs 40.3% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
45.2% (n=42) vs 0% (n=41) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
50% (n=42) vs 2.4% (n=41) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
9.5% (n=42) vs 0% (n=41) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
14.3% (n=42) vs 2.4% (n=41) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
Disease Flare 2.2% (n=274) vs 24.5% (n=269) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
1.7% (n=58) vs 20% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
1.1% (n=279) vs 25.2% (n=274) placebo15 mg QD
NCT03569293 · Phase 3
0% (n=62) vs 23.2% (n=56) placebo15 mg QD
NCT03569293 · Phase 3
1.4% (n=277) vs 24.5% (n=269) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
1.6% (n=61) vs 20% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
0% (n=285) vs 25.2% (n=274) placebo30 mg QD
NCT03569293 · Phase 3
0% (n=58) vs 23.2% (n=56) placebo30 mg QD
NCT03569293 · Phase 3
EASI 100 14.1% (n=276) vs 0.7% (n=278) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 8 more results
15.5% (n=58) vs 1.7% (n=60) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
16.7% (n=281) vs 1.8% (n=281) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
15.9% (n=63) vs 0% (n=58) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
18.8% (n=282) vs 0.7% (n=278) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
19.4% (n=62) vs 1.7% (n=60) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
27% (n=285) vs 1.8% (n=281) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
34.5% (n=58) vs 0% (n=58) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
28.4% (n=342) vs 7.9% (n=331) Dupilumab @ 16wk30 mg QD
NCT03738397 · Phase 3 · registry result, not featured evidence
WI-NRS -51.2% (n=224) vs -17.04% (n=119) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 7 more results
-47.56% (n=49) vs -11.02% (n=27) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-62.79% (n=225) vs -26.06% (n=123) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-59.01% (n=49) vs -24.36% (n=31) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-66.49% (n=235) vs -17.04% (n=119) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-66.95% (n=55) vs -11.02% (n=27) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.04% (n=236) vs -26.06% (n=123) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-70% (n=51) vs -24.36% (n=31) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
EASI -74.13% (n=246) vs -34.51% (n=142) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 69 more results
-77.85% (n=53) vs -42.19% (n=31) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-80.24% (n=244) vs -40.71% (n=128) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-82.13% (n=59) vs -43.53% (n=30) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-61.7% (n=42) vs -23% (n=39) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-65.4% (n=42) vs -17.5% (n=39) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
582.3% (n=17) vs 50.7% (n=10) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
65.7% (n=18) vs 50.7% (n=10) placebo @ 20wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
607.3% (n=17) vs 13.5% (n=10) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
72.6% (n=18) vs 13.5% (n=10) placebo @ 24wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
613.3% (n=17) vs -2.3% (n=10) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
151.7% (n=18) vs -2.3% (n=10) placebo @ 32wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
608.8% (n=17) vs -31.2% (n=10) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
154.1% (n=18) vs -31.2% (n=10) placebo @ 40wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
613.8% (n=17) vs -29.8% (n=10) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
104.1% (n=18) vs -29.8% (n=10) placebo @ 52wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
614.6% (n=17) vs -35.8% (n=10) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
104.1% (n=18) vs -35.8% (n=10) placebo @ 64wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
614% (n=17) vs -37.3% (n=10) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
130.2% (n=18) vs -37.3% (n=10) placebo @ 76wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
617.5% (n=17) vs -37.7% (n=10) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
99.3% (n=18) vs -37.7% (n=10) placebo @ 88wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-84.65% (n=250) vs -34.51% (n=142) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-84.81% (n=52) vs -42.19% (n=31) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-87.74% (n=259) vs -40.71% (n=128) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-89.42% (n=57) vs -43.53% (n=30) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-74.4% (n=42) vs -23% (n=39) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-82.8% (n=42) vs -17.5% (n=39) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
11.8% (n=10) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
791.5% (n=14) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-73.8% (n=19) vs 50.7% (n=10) placebo @ 20wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-67.5% (n=10) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
898.5% (n=14) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-69.6% (n=19) vs 13.5% (n=10) placebo @ 24wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-83.1% (n=10) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
771.5% (n=14) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-28.8% (n=19) vs -2.3% (n=10) placebo @ 32wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-92% (n=10) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
778.9% (n=14) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
140.6% (n=19) vs -31.2% (n=10) placebo @ 40wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-90.1% (n=10) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
799.5% (n=14) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-13.3% (n=19) vs -29.8% (n=10) placebo @ 52wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-91.4% (n=10) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
802.1% (n=14) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
63.6% (n=19) vs -35.8% (n=10) placebo @ 64wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-90.3% (n=10) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
787.8% (n=14) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
24.4% (n=19) vs -37.3% (n=10) placebo @ 76wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-84.6% (n=10) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
769.7% (n=14) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
39% (n=19) vs -37.7% (n=10) placebo @ 88wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-39.4% (n=42) vs -23% (n=39) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-43.7% (n=42) vs -17.5% (n=39) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
186% (n=15) vs 50.7% (n=10) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
79.1% (n=15) vs 50.7% (n=10) placebo @ 20wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
189.6% (n=15) vs 13.5% (n=10) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
59% (n=15) vs 13.5% (n=10) placebo @ 24wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
181.5% (n=15) vs -2.3% (n=10) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
63.5% (n=15) vs -2.3% (n=10) placebo @ 32wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
200.9% (n=15) vs -31.2% (n=10) placebo @ 40wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
77.6% (n=15) vs -31.2% (n=10) placebo @ 40wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
189.1% (n=15) vs -29.8% (n=10) placebo @ 52wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
74.4% (n=15) vs -29.8% (n=10) placebo @ 52wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
179.9% (n=15) vs -35.8% (n=10) placebo @ 64wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
71.8% (n=15) vs -35.8% (n=10) placebo @ 64wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
201.4% (n=15) vs -37.3% (n=10) placebo @ 76wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
77.7% (n=15) vs -37.3% (n=10) placebo @ 76wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
170.7% (n=15) vs -37.7% (n=10) placebo @ 88wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
69.1% (n=15) vs -37.7% (n=10) placebo @ 88wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
POEM 4-Point Improvement 70.9% (n=268) vs 28.7% (n=268) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
66.1% (n=56) vs 28.1% (n=57) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75% (n=278) vs 22.8% (n=276) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
80.6% (n=62) vs 27.3% (n=55) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
83.5% (n=269) vs 28.7% (n=268) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
80.7% (n=57) vs 28.1% (n=57) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
81.4% (n=280) vs 22.8% (n=276) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
87.9% (n=58) vs 27.3% (n=55) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
DLQI 4-point Improvement 71.7% (n=251) vs 28.4% (n=250) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
68.2% (n=22) vs 19.2% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
75.4% (n=254) vs 29% (n=250) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
81.5% (n=27) vs 33.3% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
77.6% (n=251) vs 28.4% (n=250) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
73.3% (n=30) vs 19.2% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
82% (n=256) vs 29% (n=250) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
79.3% (n=29) vs 33.3% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
SCORAD -57.9% (n=245) vs -28.43% (n=136) placebo @ 16wk15 mg QD
percent change · % of baseline
NCT03607422 · Phase 3
show 13 more results
-57.89% (n=54) vs -27.91% (n=30) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
-65.71% (n=239) vs -32.68% (n=125) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-65.42% (n=58) vs -30.9% (n=30) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
-44.1% (n=36) vs -7% (n=33) placebo @ 8wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-46.9% (n=36) vs -12.4% (n=33) placebo @ 16wk15 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-68.44% (n=241) vs -28.43% (n=136) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-72.81% (n=49) vs -27.91% (n=30) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
-73.07% (n=253) vs -32.68% (n=125) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-76.35% (n=57) vs -30.9% (n=30) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
-65.3% (n=40) vs -7% (n=33) placebo @ 8wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-60.4% (n=40) vs -12.4% (n=33) placebo @ 16wk30 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-35.4% (n=39) vs -7% (n=33) placebo @ 8wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
-32.5% (n=39) vs -12.4% (n=33) placebo @ 16wk7.5 mg
NCT02925117 · Phase 2 · registry result, not featured evidence
DLQI 0/1 23.8% (n=252) vs 4.7% (n=257) placebo @ 16wk15 mg QD
responder rate · % of participants
NCT03607422 · Phase 3
show 7 more results
13.6% (n=22) vs 7.7% (n=26) placebo @ 16wk15 mg QD
NCT03607422 · Phase 3
30.3% (n=258) vs 4.4% (n=252) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
22.2% (n=27) vs 4.8% (n=21) placebo @ 16wk15 mg QD
NCT03569293 · Phase 3
37.9% (n=256) vs 4.7% (n=257) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
46.9% (n=32) vs 7.7% (n=26) placebo @ 16wk30 mg QD
NCT03607422 · Phase 3
41.5% (n=261) vs 4.4% (n=252) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3
30% (n=30) vs 4.8% (n=21) placebo @ 16wk30 mg QD
NCT03569293 · Phase 3

+ 25 further endpoints in the CSV export.

Rheumatoid Arthritis

Shared mechanism: JAK1 · full Rheumatoid Arthritis pipeline

upadacitinib · Rinvoq

Marketed by AbbVie

Approved in Rheumatoid ArthritisSmall molecule (JAK1-selective inhibitor)
Reliable signal

NCT02675426 · Phase 3 · completed

This was a randomized, quadruple-blind, placebo-controlled trial in 661 patients using two validated rheumatoid arthritis disease-activity measures as co-primary endpoints, and both upadacitinib doses produced significantly higher response rates than placebo on both measures (all comparisons p<0.001).

Next expected readout: March 2027 · NCT07636057 (registry estimate)

Reported efficacy

Change From Baseline in Disease Activity Score (DAS) 28 C-Reactive Protein (CRP) at Week 12 (Non-inferiority) (Baseline and Week 12): Change from baseline DAS28-CRP at week 12: -2.52 (95% CI -2.66 to -2.37) upadacitinib vs -2.00 (95% CI -2.14 to -1.85) abatacept; upadacitinib met primary non-inferiority and key secondary superiority endpoints. (met)

Result source: NCT03086343

Zemprocitinib

Developed by Lynk Pharmaceuticals and partners

Phase 3 in Rheumatoid Arthritissmall molecule
not yet graded

No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.

No aligned efficacy figure on record for this race.

Results for Rheumatoid Arthritis

Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.

Key endpointupadacitinibZemprocitinib
ACR2063.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
—Not posted · NCT06276998
ACR5052.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
—Not posted · NCT06276998
ACR7020.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
—Not posted · NCT06276998
DAS28-CRP remission48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
—Not posted · NCT06276998
HAQ-DI, change-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705
—Not posted · NCT06276998
Modified Sharp score, change0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873
—Not posted · NCT06276998

ACR20

upadacitinib
63.8% vs 35.7%+28.1 vs placebo15 mg · wk 12 · n 221NCT02675426
49 other results
  • 64.6% vs 28.4% 15 mg · wk 12 · n 164 · Phase 3 · primary NCT02706847
  • 71.6% vs 31.4% 15 mg · wk 12 · n 169 · Phase 3 · primary NCT02955212
  • 66.2% vs 35.7% 30 mg · wk 12 · n 219 · Phase 3 · primary NCT02675426
  • 56.4% vs 28.4% 30 mg · wk 12 · n 165 · Phase 3 · primary NCT02706847
  • 83.7% vs 42.9% 15 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 80% vs 42.9% 30 mg · wk 12 · n 50 · Phase 2/3 · primary NCT02720523
  • 75.5% vs 42.9% 7.5 mg · wk 12 · n 49 · Phase 2/3 · primary NCT02720523
  • 67.7% vs 41.2% 15 mg · wk 14 · n 217 · Phase 3 · primary NCT02706951
  • 75.7% vs 54.1% 15 mg · wk 12 · n 317 · Phase 3 · primary NCT02706873
  • 71.2% vs 41.2% 30 mg · wk 14 · n 215 · Phase 3 · primary NCT02706951
  • 77.1% vs 54.1% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 22.2% vs 8.6% 15 mg · wk 1 · n 221 · Phase 3 · secondary NCT02675426
  • 27.4% vs 10.7% 15 mg · wk 1 · n 164 · Phase 3 · secondary NCT02706847
  • 25.4% vs 5.9% 15 mg · wk 1 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 8.6% 30 mg · wk 1 · n 219 · Phase 3 · secondary NCT02675426
  • 24.8% vs 10.7% 30 mg · wk 1 · n 165 · Phase 3 · secondary NCT02706847
  • 24.5% vs 8.2% 15 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 34% vs 8.2% 30 mg · wk 1 · n 50 · Phase 2/3 · secondary NCT02720523
  • 30.6% vs 8.2% 7.5 mg · wk 1 · n 49 · Phase 2/3 · secondary NCT02720523
  • 78.9% vs 58.6% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 78% vs 58.6% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 85.2% vs 57.1% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 78.6% vs 57.1% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 85.5% vs 57.1% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 81.6% vs 50% 24 mg QD · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 76.6% vs 50% 18 mg BID · wk 12 · n 47 · Phase 2 · primary NCT02066389
  • 70.9% vs 35.2% 18 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 81.6% vs 50% 12 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 72.7% vs 35.2% 12 mg BID · wk 12 · n 55 · Phase 2 · primary NCT01960855
  • 73.5% vs 50% 6 mg BID · wk 12 · n 49 · Phase 2 · primary NCT02066389
  • 63.5% vs 35.2% 6 mg BID · wk 12 · n 52 · Phase 2 · primary NCT01960855
  • 64.6% vs 50% 3 mg BID · wk 12 · n 48 · Phase 2 · primary NCT02066389
  • 55.6% vs 35.2% 3 mg BID · wk 12 · n 54 · Phase 2 · primary NCT01960855
  • 41.5% vs 47.4% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 29.3% vs 42.1% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 24.4% vs 21.1% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 30.8% vs 47.4% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 30.8% vs 36.8% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 23.1% vs 42.1% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 21.1% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 64.5% vs 47.4% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 64.5% vs 36.8% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 51.6% vs 42.1% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 45.2% vs 21.1% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 34.1% vs 47.4% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 39% vs 36.8% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 22% vs 42.1% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 14.6% vs 21.1% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
Zemprocitinib
—Not posted · NCT06276998

ACR50

upadacitinib
52.1% vs 28.3%vs Methotrexate15 mg · wk 12 · n 317NCT02706873
41 other results
  • 56.4% vs 28.3% 30 mg · wk 12 · n 314 · Phase 3 · primary NCT02706873
  • 38% vs 14.9% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 34.1% vs 11.8% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 40.8% vs 8.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 43.4% vs 14.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 35.8% vs 11.8% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 65.3% vs 16.3% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 58% vs 16.3% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 40.8% vs 16.3% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 60.3% vs 33.4% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 41.9% vs 15.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 65.6% vs 33.4% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 52.1% vs 15.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 66.7% vs 21.4% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 71.4% vs 21.4% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 60% vs 21.4% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 29.3% vs 21.1% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 19.5% vs 5.3% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 17.1% vs 10.5% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 43.8% vs 19.6% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 12.8% vs 21.1% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 12.8% vs 5.3% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 10.5% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 44.7% vs 19.6% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 40% vs 17% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 45.2% vs 21.1% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 41.9% vs 5.3% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 19.4% vs 10.5% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 16.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 50% vs 19.6% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 43.6% vs 17% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 49% vs 19.6% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 38.5% vs 17% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 17.1% vs 21.1% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 7.3% vs 5.3% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 10.5% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 39.6% vs 19.6% 3 mg BID · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 24.1% vs 17% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
Zemprocitinib
—Not posted · NCT06276998

ACR70

upadacitinib
20.8% vs 5.9%+14.9 vs placebo15 mg · wk 12 · n 221NCT02675426
41 other results
  • 11.6% vs 6.5% 15 mg · wk 12 · n 164 · Phase 3 · secondary NCT02706847
  • 21.3% vs 3.6% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 26.5% vs 5.9% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 23% vs 6.5% 30 mg · wk 12 · n 165 · Phase 3 · secondary NCT02706847
  • 34.7% vs 2% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28% vs 2% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 20.4% vs 2% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 44.5% vs 18.5% 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • 22.6% vs 2.8% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 32.5% vs 14% 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • 49.7% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · secondary NCT02706873
  • 33% vs 2.8% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 36.9% vs 14% 30 mg · wk 12 · n 314 · Phase 3 · secondary NCT02706873
  • 51.9% vs 0% 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • 64.3% vs 0% 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • 34.5% vs 0% 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • 14.6% vs 15.8% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 4.9% vs 0% 60 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 2.4% vs 0% 60 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 25% vs 6.5% 24 mg QD · wk 12 · n 48 · Phase 2 · secondary NCT02066389
  • 5.1% vs 15.8% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • 2.6% vs 0% 20 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 20 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • 27.7% vs 6.5% 18 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 18 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 25.8% vs 15.8% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 17.7% vs 0% 15 mg/60 mg · wk 8 · n 62 · Phase 2 · secondary NCT03682705
  • 9.7% vs 0% 15 mg/60 mg · wk 4 · n 62 · Phase 2 · secondary NCT03682705
  • 8.1% vs 0% 15 mg/60 mg · wk 2 · n 62 · Phase 2 · secondary NCT03682705
  • 16% vs 6.5% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 21.8% vs 3.6% 12 mg BID · wk 12 · n 55 · Phase 2 · secondary NCT01960855
  • 30.6% vs 6.5% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 26.9% vs 3.6% 6 mg BID · wk 12 · n 52 · Phase 2 · secondary NCT01960855
  • 9.8% vs 15.8% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 8 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 4 · n 41 · Phase 2 · secondary NCT03682705
  • 0% vs 0% 5 mg · wk 2 · n 41 · Phase 2 · secondary NCT03682705
  • 23.4% vs 6.5% 3 mg BID · wk 12 · n 47 · Phase 2 · secondary NCT02066389
  • 13% vs 3.6% 3 mg BID · wk 12 · n 54 · Phase 2 · secondary NCT01960855
Zemprocitinib
—Not posted · NCT06276998

DAS28-CRP remission

upadacitinib
48.3% vs 18.5%vs Methotrexate15 mg · wk 24 · n 317NCT02706873
22 other results
  • 50% vs 18.5% 30 mg · wk 24 · n 314 · Phase 3 · primary NCT02706873
  • 30.8% vs 10% 15 mg · wk 12 · n 221 · Phase 3 · secondary NCT02675426
  • 29.6% vs 5.3% 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • 28.3% vs 10% 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • 57.1% vs 6.1% 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 50% vs 6.1% 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • 36.7% vs 6.1% 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • 28.1% vs 8.3% 15 mg · wk 14 · n 217 · Phase 3 · secondary NCT02706951
  • 30% vs 13.3% 15 mg QD · wk 12 · n 303 · Phase 3 · secondary NCT03086343
  • 40.5% vs 8.3% 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • 70.4% vs 17.9% 15 mg · wk 24 · n 27 · Phase 3 · secondary NCT02706873
  • 82.1% vs 17.9% 30 mg · wk 24 · n 28 · Phase 3 · secondary NCT02706873
  • 67.3% vs 17.9% 7.5 mg · wk 24 · n 55 · Phase 3 · secondary NCT02706873
  • 19.5% vs 10.5% 60 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 22.4% vs 14.9% 24 mg QD · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 7.7% vs 10.5% 20 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • 42.9% vs 14.9% 18 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 32.3% vs 10.5% 15 mg/60 mg · wk 12 · n 62 · Phase 2 · secondary NCT03682705
  • 34% vs 14.9% 12 mg BID · wk 12 · n 50 · Phase 2 · secondary NCT02066389
  • 38.8% vs 14.9% 6 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
  • 9.8% vs 10.5% 5 mg · wk 12 · n 41 · Phase 2 · secondary NCT03682705
  • 36.7% vs 14.9% 3 mg BID · wk 12 · n 49 · Phase 2 · secondary NCT02066389
Zemprocitinib
—Not posted · NCT06276998

HAQ-DI, change

upadacitinib
-0.6 vs -0.3−0.3 vs placebo15 mg · wk 12 · n 216NCT02675426
32 other results
  • -0.4 vs -0.2 15 mg · wk 12 · n 163 · Phase 3 · secondary NCT02706847
  • -0.6 vs -0.2 15 mg · wk 12 · n 169 · Phase 3 · secondary NCT02955212
  • -0.5 vs -0.3 30 mg · wk 12 · n 219 · Phase 3 · secondary NCT02675426
  • -0.4 vs -0.2 30 mg · wk 12 · n 160 · Phase 3 · secondary NCT02706847
  • -0.5 vs -0.1 15 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.5 vs -0.1 30 mg · wk 12 · n 50 · Phase 2/3 · secondary NCT02720523
  • -0.4 vs -0.1 7.5 mg · wk 12 · n 49 · Phase 2/3 · secondary NCT02720523
  • -0.9 vs -0.6 15 mg · wk 24 · n 317 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 15 mg · wk 14 · n 216 · Phase 3 · secondary NCT02706951
  • -0.8 vs -0.5 15 mg · wk 12 · n 317 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.6 30 mg · wk 24 · n 310 · Phase 3 · secondary NCT02706873
  • -0.7 vs -0.3 30 mg · wk 14 · n 215 · Phase 3 · secondary NCT02706951
  • -0.9 vs -0.5 30 mg · wk 12 · n 310 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 15 mg · wk 12 · n 27 · Phase 3 · secondary NCT02706873
  • -0.9 vs -0.2 30 mg · wk 12 · n 28 · Phase 3 · secondary NCT02706873
  • -0.8 vs -0.2 7.5 mg · wk 12 · n 55 · Phase 3 · secondary NCT02706873
  • -0.3 vs -0.3 60 mg · wk 12 · n 39 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 60 mg · wk 8 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 60 mg · wk 4 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 60 mg · wk 2 · n 39 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.3 20 mg · wk 12 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 8 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.4 20 mg · wk 4 · n 35 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 20 mg · wk 2 · n 35 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.3 15 mg/60 mg · wk 12 · n 59 · Phase 2 · secondary NCT03682705
  • -0.5 vs -0.2 15 mg/60 mg · wk 8 · n 59 · Phase 2 · secondary NCT03682705
  • -0.4 vs -0.4 15 mg/60 mg · wk 4 · n 59 · Phase 2 · secondary NCT03682705
  • -0.3 vs -0.2 15 mg/60 mg · wk 2 · n 59 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.3 5 mg · wk 12 · n 40 · Phase 2 · secondary NCT03682705
  • -0.1 vs -0.2 5 mg · wk 8 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.4 5 mg · wk 4 · n 40 · Phase 2 · secondary NCT03682705
  • -0.2 vs -0.2 5 mg · wk 2 · n 40 · Phase 2 · secondary NCT03682705
Zemprocitinib
—Not posted · NCT06276998

Modified Sharp score, change

upadacitinib
0.1 vs 0.7vs Methotrexate15 mg · wk 24 · n 279NCT02706873
4 other results
  • 0.1 vs 0.7 30 mg · wk 24 · n 270 · Phase 3 · primary NCT02706873
  • 0.2 vs 2.6 15 mg · wk 24 · n 26 · Phase 3 · secondary NCT02706873
  • 0.2 vs 2.6 30 mg · wk 24 · n 24 · Phase 3 · secondary NCT02706873
  • 0.9 vs 2.6 7.5 mg · wk 24 · n 51 · Phase 3 · secondary NCT02706873
Zemprocitinib
—Not posted · NCT06276998
  1. Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
  2. An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.

Zemprocitinib: no structured comparison results are available for Rheumatoid Arthritis.

Only safety results can currently be compared in this indication. Reviewed efficacy summaries, where available, are listed separately.

safety

Coverage. upadacitinib: 4 of 4 rows · Zemprocitinib: 0 of 4 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.

Reported metricupadacitinib
Dropout rate
—15 mga
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.6%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
8.2%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
12.6%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
14%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
7.3%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
7.4%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
4.7%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
4.8%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
9.7%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.1%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
7.3%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
6.5%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
14.6%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
10%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
14%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
6%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
12%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.1%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
16.4%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
7.3%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Discontinued due to AEs
—15 mga
NCT02675426 · Phase 3
show 55 more results
—15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
1.4%15 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
4.1%30 mg
NCT02675426 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
5.7%15 mg
NCT02706873 · Phase 3
—15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3 · monotherapy
3.5%30 mg
NCT02706873 · Phase 3
—30 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3 · monotherapy
5.5%7.5 mg
NCT02706873 · Phase 3
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg QD
NCT03086343 · Phase 3
—15 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
—30 mg QD
NCT03086343 · Phase 3
2.3%15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
—15 mg
NCT02706951 · Phase 3
1.4%30 mg
NCT02706951 · Phase 3
—30 mg
NCT02706951 · Phase 3
0.6%15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
—15 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
—15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
0%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
—12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
—6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
2.4%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
1.6%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
2.4%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
10%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
3.6%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
10.9%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Serious AEs
28.1%15 mga
NCT02675426 · Phase 3
show 55 more results
4.5%15 mg
NCT02675426 · Phase 3
10.6%15 mg
NCT02675426 · Phase 3
—15 mg
NCT02675426 · Phase 3
3.2%30 mg
NCT02675426 · Phase 3
31.8%30 mg
NCT02675426 · Phase 3
—30 mg
NCT02675426 · Phase 3
15.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—15 mg
NCT02706873 · Phase 3
5%15 mg
NCT02706873 · Phase 3 · monotherapy
21.5%15 mg
NCT02706873 · Phase 3 · monotherapy
—30 mg
NCT02706873 · Phase 3
6.4%30 mg
NCT02706873 · Phase 3 · monotherapy
22.6%30 mg
NCT02706873 · Phase 3 · monotherapy
—7.5 mg
NCT02706873 · Phase 3
9.1%7.5 mg
NCT02706873 · Phase 3 · monotherapy
23.6%7.5 mg
NCT02706873 · Phase 3 · monotherapy
4%15 mg QD
NCT03086343 · Phase 3
23.6%15 mg QD
NCT03086343 · Phase 3
19%30 mg QD
NCT03086343 · Phase 3
35.3%30 mg QD
NCT03086343 · Phase 3
5.1%15 mg
NCT02706951 · Phase 3
10.7%15 mg
NCT02706951 · Phase 3
29.9%15 mg
NCT02706951 · Phase 3
2.8%30 mg
NCT02706951 · Phase 3
24.1%30 mg
NCT02706951 · Phase 3
—15 mg
NCT02706847 · Phase 3
15.2%15 mg
NCT02706847 · Phase 3
5.5%15 mg
NCT02706847 · Phase 3
36.9%15 mg
NCT02706847 · Phase 3
—30 mg
NCT02706847 · Phase 3
7.3%30 mg
NCT02706847 · Phase 3
29.6%30 mg
NCT02706847 · Phase 3
17.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
7.1%15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
21.9%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
27.3%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
10%30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
13.8%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2%7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
22.5%12 mg BID/30 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
13.8%6 mg BID/15 mg QD
NCT02049138 · Phase 2 · registry result, not featured evidence
0%60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1%20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0%15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
7.3%5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.1%24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
6%18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2%12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
4%6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
0%3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
1.8%18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
0%12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
3.6%3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence
Most frequent reported AEs
15 mga
upper respiratory tract infection 19.8% (placebo 4.1%)
nasopharyngitis 18.5% (placebo 4.1%)
urinary tract infection 17% (placebo 3.6%)
NCT02675426 · Phase 3
show 48 more results
15 mg
nausea 6.8% (placebo 3.2%)
nasopharyngitis 5.4% (placebo 4.1%)
upper respiratory tract infection 5.4% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 8.9% (placebo 0%)
rheumatoid arthritis 4.5% (placebo 4.5%)
fall 2.8% (placebo 0.5%)
NCT02675426 · Phase 3
30 mg
nasopharyngitis 5.9% (placebo 4.1%)
upper respiratory tract infection 5.5% (placebo 4.1%)
headache 3.7% (placebo 5.4%)
NCT02675426 · Phase 3
30 mg
upper respiratory tract infection 17.8% (placebo 4.1%)
urinary tract infection 14.3% (placebo 3.6%)
nasopharyngitis 14% (placebo 4.1%)
NCT02675426 · Phase 3
15 mg
covid-19 10.5%
rheumatoid arthritis 9.4%
urinary tract infection 7.2%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 6.3%
nasopharyngitis 5.7%
nausea 5.7%
NCT02706873 · Phase 3 · monotherapy
15 mg
upper respiratory tract infection 15.5%
nasopharyngitis 15.1%
urinary tract infection 13.6%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 10.8%
upper respiratory tract infection 7.3%
urinary tract infection 5.7%
NCT02706873 · Phase 3 · monotherapy
30 mg
blood creatine phosphokinase increased 16.2%
nasopharyngitis 16.2%
hypertension 14%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 9.1%
pharyngitis 9.1%
stomatitis 7.3%
NCT02706873 · Phase 3 · monotherapy
7.5 mg
nasopharyngitis 40%
herpes zoster 21.8%
pharyngitis 21.8%
NCT02706873 · Phase 3 · monotherapy
15 mg QD
upper respiratory tract infection 8.6%
nasopharyngitis 7.3%
urinary tract infection 6.6%
NCT03086343 · Phase 3
15 mg QD
covid-19 23.6%
urinary tract infection 14.8%
nasopharyngitis 13.7%
NCT03086343 · Phase 3
30 mg QD
rheumatoid arthritis 14.3%
arthralgia 9.5%
cough 9.5%
NCT03086343 · Phase 3
30 mg QD
hypertension 23.5%
upper respiratory tract infection 23.5%
bronchitis 17.6%
NCT03086343 · Phase 3
15 mg
urinary tract infection 4.6%
upper respiratory tract infection 4.1%
blood creatine phosphokinase increased 2.3%
NCT02706951 · Phase 3
15 mg
covid-19 9.8%
urinary tract infection 6.3%
rheumatoid arthritis 4.4%
NCT02706951 · Phase 3
15 mg
nasopharyngitis 17.6%
rheumatoid arthritis 14.2%
urinary tract infection 13.5%
NCT02706951 · Phase 3
30 mg
urinary tract infection 4.7%
blood creatine phosphokinase increased 4.2%
upper respiratory tract infection 2.8%
NCT02706951 · Phase 3
30 mg
blood creatine phosphokinase increased 18.6%
urinary tract infection 15.1%
upper respiratory tract infection 14.8%
NCT02706951 · Phase 3
15 mg
rheumatoid arthritis 9.4% (placebo 5.9%)
urinary tract infection 8% (placebo 5.9%)
back pain 5.8% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
urinary tract infection 9.8% (placebo 5.9%)
upper respiratory tract infection 7.9% (placebo 7.7%)
bronchitis 4.3% (placebo 2.4%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 31.4% (placebo 7.7%)
urinary tract infection 18.2% (placebo 5.9%)
nasopharyngitis 14.4% (placebo 6.5%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 6.7% (placebo 7.7%)
nasopharyngitis 5.5% (placebo 6.5%)
urinary tract infection 5.5% (placebo 5.9%)
NCT02706847 · Phase 3
30 mg
upper respiratory tract infection 27.9% (placebo 7.7%)
urinary tract infection 20.4% (placebo 5.9%)
nasopharyngitis 17.1% (placebo 6.5%)
NCT02706847 · Phase 3
15 mg
upper respiratory tract infection 20.2% (placebo 6.5%)
alanine aminotransferase increased 9.3% (placebo 1.2%)
blood creatine phosphokinase increased 9% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
upper respiratory tract infection 9.5% (placebo 6.5%)
alanine aminotransferase increased 5.3% (placebo 1.2%)
anaemia 0% (placebo 0%)
NCT02955212 · Phase 3 · registry result, not featured evidence
15 mg
nasopharyngitis 54.7% (placebo 10.2%)
herpes zoster 14.1% (placebo 2%)
influenza 14.1% (placebo 4.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
15 mg
nasopharyngitis 12.2% (placebo 10.2%)
liver function test increased 6.1% (placebo 0%)
constipation 4.1% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 43.9% (placebo 10.2%)
constipation 15.2% (placebo 0%)
herpes zoster 15.2% (placebo 2%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30 mg
nasopharyngitis 18% (placebo 10.2%)
blood creatine phosphokinase increased 6% (placebo 0%)
headache 6% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 53.8% (placebo 10.2%)
stomatitis 20% (placebo 6.1%)
hypertension 12.3% (placebo 0%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.5 mg
nasopharyngitis 10.2% (placebo 10.2%)
hypertension 6.1% (placebo 0%)
stomatitis 6.1% (placebo 6.1%)
NCT02720523 · Phase 2/3 · registry result, not featured evidence
12 mg BID/30 mg QD
upper respiratory tract infection 20.3%
urinary tract infection 15%
herpes zoster 11.2%
NCT02049138 · Phase 2 · registry result, not featured evidence
6 mg BID/15 mg QD
upper respiratory tract infection 9.9%
nasopharyngitis 9.5%
urinary tract infection 9.5%
NCT02049138 · Phase 2 · registry result, not featured evidence
60 mg
urinary tract infection 9.8% (placebo 0%)
diarrhoea 7.3% (placebo 0%)
rheumatoid arthritis 7.3% (placebo 10.5%)
NCT03682705 · Phase 2 · registry result, not featured evidence
20 mg
rheumatoid arthritis 7.7% (placebo 10.5%)
upper respiratory tract infection 7.7% (placebo 5.3%)
alopecia 5.1% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
15 mg/60 mg
upper respiratory tract infection 6.5% (placebo 5.3%)
arthralgia 1.6% (placebo 5.3%)
cough 1.6% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
5 mg
rheumatoid arthritis 7.3% (placebo 10.5%)
upper respiratory tract infection 4.9% (placebo 5.3%)
urinary tract infection 4.9% (placebo 0%)
NCT03682705 · Phase 2 · registry result, not featured evidence
24 mg QD
nasopharyngitis 6.1% (placebo 2%)
back pain 2% (placebo 0%)
blood creatine phosphokinase increased 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
blood creatine phosphokinase increased 4% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
12 mg BID
influenza 8% (placebo 0%)
nasopharyngitis 8% (placebo 2%)
blood creatine phosphokinase increased 6% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
6 mg BID
back pain 6% (placebo 0%)
nasopharyngitis 4% (placebo 2%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
3 mg BID
headache 4% (placebo 2%)
back pain 2% (placebo 0%)
cough 2% (placebo 0%)
NCT02066389 · Phase 2 · registry result, not featured evidence
18 mg BID
urinary tract infection 12.7% (placebo 3.6%)
blood creatine phosphokinase increased 9.1% (placebo 0%)
constipation 7.3% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
12 mg BID
upper respiratory tract infection 7.3% (placebo 1.8%)
headache 5.5% (placebo 1.8%)
leukopenia 5.5% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
6 mg BID
headache 5.5% (placebo 1.8%)
hyperlipidaemia 3.6% (placebo 1.8%)
constipation 1.8% (placebo 0%)
NCT01960855 · Phase 2 · registry result, not featured evidence
3 mg BID
nausea 7.3% (placebo 1.8%)
arthralgia 5.5% (placebo 0%)
headache 5.5% (placebo 1.8%)
NCT01960855 · Phase 2 · registry result, not featured evidence

Notes

  1. aPopulation comparability has not been reviewed for these studies.

Reported by one asset only

Endpoints only one of the selected assets measured, so there is nothing to compare them against.

upadacitinib

ACR20 63.8% (n=221) vs 35.7% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 49 more results
22.2% (n=221) vs 8.6% (n=221) placebo @ 1wk15 mg
NCT02675426 · Phase 3
75.7% (n=317) vs 54.1% (n=314) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
78.9% (n=317) vs 58.6% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
85.2% (n=27) vs 57.1% (n=28) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
67.7% (n=217) vs 41.2% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
64.6% (n=164) vs 28.4% (n=169) placebo @ 12wk15 mg
NCT02706847 · Phase 3
27.4% (n=164) vs 10.7% (n=169) placebo @ 1wk15 mg
NCT02706847 · Phase 3
71.6% (n=169) vs 31.4% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
25.4% (n=169) vs 5.9% (n=169) placebo @ 1wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
83.7% (n=49) vs 42.9% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
24.5% (n=49) vs 8.2% (n=49) placebo @ 1wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
66.2% (n=219) vs 35.7% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
28.3% (n=219) vs 8.6% (n=221) placebo @ 1wk30 mg
NCT02675426 · Phase 3
77.1% (n=314) vs 54.1% (n=314) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
78% (n=314) vs 58.6% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
78.6% (n=28) vs 57.1% (n=28) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
71.2% (n=215) vs 41.2% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
56.4% (n=165) vs 28.4% (n=169) placebo @ 12wk30 mg
NCT02706847 · Phase 3
24.8% (n=165) vs 10.7% (n=169) placebo @ 1wk30 mg
NCT02706847 · Phase 3
80% (n=50) vs 42.9% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
34% (n=50) vs 8.2% (n=49) placebo @ 1wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
85.5% (n=55) vs 57.1% (n=28) Methotrexate @ 12wk7.5 mg
NCT02706873 · Phase 3
75.5% (n=49) vs 42.9% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
30.6% (n=49) vs 8.2% (n=49) placebo @ 1wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
24.4% (n=41) vs 21.1% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
29.3% (n=41) vs 42.1% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
39% (n=41) vs 36.8% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
41.5% (n=41) vs 47.4% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
81.6% (n=49) vs 50% (n=46) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
12.8% (n=39) vs 21.1% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
23.1% (n=39) vs 42.1% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
30.8% (n=39) vs 36.8% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
30.8% (n=39) vs 47.4% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
76.6% (n=47) vs 50% (n=46) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
70.9% (n=55) vs 35.2% (n=54) placebo @ 12wk*18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 39 Participants as posted
45.2% (n=62) vs 21.1% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
51.6% (n=62) vs 42.1% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
64.5% (n=62) vs 36.8% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
64.5% (n=62) vs 47.4% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
81.6% (n=49) vs 50% (n=46) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
72.7% (n=55) vs 35.2% (n=54) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 40 Participants as posted
73.5% (n=49) vs 50% (n=46) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
63.5% (n=52) vs 35.2% (n=54) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 33 Participants as posted
14.6% (n=41) vs 21.1% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
22% (n=41) vs 42.1% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
39% (n=41) vs 36.8% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
34.1% (n=41) vs 47.4% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
64.6% (n=48) vs 50% (n=46) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
55.6% (n=54) vs 35.2% (n=54) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 30 Participants as posted
DAS Low Disease Activity 48.4% (n=221) vs 17.2% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 21 more results
53.3% (n=317) vs 28.3% (n=314) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
59.9% (n=317) vs 32.2% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
77.8% (n=27) vs 17.9% (n=28) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
44.7% (n=217) vs 19.4% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
43.3% (n=164) vs 14.2% (n=169) placebo @ 12wk15 mg
NCT02706847 · Phase 3
46.2% (n=169) vs 13.6% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
69.4% (n=49) vs 18.4% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
47.9% (n=219) vs 17.2% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
54.8% (n=314) vs 28.3% (n=314) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
65% (n=314) vs 32.2% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
78.6% (n=28) vs 17.9% (n=28) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
53% (n=215) vs 19.4% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
42.4% (n=165) vs 14.2% (n=169) placebo @ 12wk30 mg
NCT02706847 · Phase 3
72% (n=50) vs 18.4% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
69.1% (n=55) vs 17.9% (n=28) Methotrexate @ 12wk7.5 mg
NCT02706873 · Phase 3
53.1% (n=49) vs 18.4% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
42.9% (n=49) vs 21.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
51% (n=49) vs 21.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
46% (n=50) vs 21.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
57.1% (n=49) vs 21.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
49% (n=49) vs 21.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
DAS28-CRP -2.2 vs -1.02 placebo score @ 12wk15 mg
absolute change · score
NCT02675426 · Phase 3
show 38 more results
-2.73 vs -1.85 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
-3.07 vs -2.15 Methotrexate score @ 24wk15 mg
NCT02706873 · Phase 3
-3.28 vs -1.42 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
-2.52 vs -2 Abatacept score @ 12wk15 mg QD
NCT03086343 · Phase 3
-2.52 vs -2 Abatacept score @ 12wk15 mg QD
NCT03086343 · Phase 3
-2.29 vs -1.2 Methotrexate score @ 14wk15 mg
NCT02706951 · Phase 3
-2.31 vs -1.02 placebo score @ 12wk15 mg
NCT02706847 · Phase 3
-2.56 vs -0.95 placebo score @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
-2.39 vs -0.79 placebo score @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-2.34 vs -1.02 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
-2.85 vs -1.85 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
-3.34 vs -2.15 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
-3.34 vs -1.42 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
-2.61 vs -1.2 Methotrexate score @ 14wk30 mg
NCT02706951 · Phase 3
-2.29 vs -1.02 placebo score @ 12wk30 mg
NCT02706847 · Phase 3
-2.41 vs -0.79 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-2.86 vs -1.42 Methotrexate score @ 12wk7.5 mg
NCT02706873 · Phase 3
-2.08 vs -0.79 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-1.52 vs -1.12 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.63 vs -0.46 placebo score @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.87 vs -0.9 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.21 vs -0.78 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.52 vs -1.12 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.32 vs -1.12 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.44 vs -0.46 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.68 vs -0.9 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.24 vs -0.78 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.32 vs -1.12 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-2.56 vs -1.12 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.53 vs -0.46 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.96 vs -0.9 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.4 vs -0.78 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-2.56 vs -1.12 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-1.33 vs -1.12 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.56 vs -0.46 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.82 vs -0.9 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.11 vs -0.78 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-1.33 vs -1.12 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
HAQ-DI -0.59 vs -0.25 placebo score @ 12wk15 mg
absolute change · score
NCT02675426 · Phase 3
show 32 more results
-0.83 vs -0.49 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
-0.87 vs -0.6 Methotrexate score @ 24wk15 mg
NCT02706873 · Phase 3
-0.95 vs -0.2 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
-0.65 vs -0.32 Methotrexate score @ 14wk15 mg
NCT02706951 · Phase 3
-0.39 vs -0.17 placebo score @ 12wk15 mg
NCT02706847 · Phase 3
-0.62 vs -0.18 placebo score @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
-0.45 vs -0.1 placebo score @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.54 vs -0.25 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
-0.86 vs -0.49 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
-0.91 vs -0.6 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
-0.95 vs -0.2 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
-0.73 vs -0.32 Methotrexate score @ 14wk30 mg
NCT02706951 · Phase 3
-0.42 vs -0.17 placebo score @ 12wk30 mg
NCT02706847 · Phase 3
-0.49 vs -0.1 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.75 vs -0.2 Methotrexate score @ 12wk7.5 mg
NCT02706873 · Phase 3
-0.41 vs -0.1 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
-0.13 vs -0.22 placebo score @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.11 vs -0.36 placebo score @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.29 vs -0.24 placebo score @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.31 vs -0.3 placebo score @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.06 vs -0.22 placebo score @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.14 vs -0.36 placebo score @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.15 vs -0.24 placebo score @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.12 vs -0.3 placebo score @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.34 vs -0.22 placebo score @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.39 vs -0.36 placebo score @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.47 vs -0.24 placebo score @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.52 vs -0.3 placebo score @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
-0.16 vs -0.22 placebo score @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.21 vs -0.36 placebo score @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.15 vs -0.24 placebo score @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
-0.18 vs -0.3 placebo score @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
SF-36 PCS 7.58 vs 3.03 placebo score @ 12wk15 mg
absolute change · score
NCT02675426 · Phase 3
show 16 more results
9.99 vs 5.74 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
10.7 vs 6.97 Methotrexate score @ 24wk15 mg
NCT02706873 · Phase 3
10.79 vs 2.87 Methotrexate score @ 12wk15 mg
NCT02706873 · Phase 3
8.28 vs 4.32 Methotrexate score @ 14wk15 mg
NCT02706951 · Phase 3
5.83 vs 2.39 placebo score @ 12wk15 mg
NCT02706847 · Phase 3
8.93 vs 3.36 placebo score @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
6.38 vs 2.88 placebo score @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
8.01 vs 3.03 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
10.08 vs 5.74 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
11.39 vs 6.97 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
9.63 vs 2.87 Methotrexate score @ 12wk30 mg
NCT02706873 · Phase 3
10.19 vs 4.32 Methotrexate score @ 14wk30 mg
NCT02706951 · Phase 3
7.02 vs 2.39 placebo score @ 12wk30 mg
NCT02706847 · Phase 3
8.81 vs 2.88 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
8.84 vs 2.87 Methotrexate score @ 12wk7.5 mg
NCT02706873 · Phase 3
7.21 vs 2.88 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
DAS28 (CRP) Remission 30.8% (n=221) vs 10% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 22 more results
48.3% (n=317) vs 18.5% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
70.4% (n=27) vs 17.9% (n=28) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
30% (n=303) vs 13.3% (n=309) Abatacept @ 12wk15 mg QD
NCT03086343 · Phase 3
28.1% (n=217) vs 8.3% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
29.6% (n=169) vs 5.3% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
57.1% (n=49) vs 6.1% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
28.3% (n=219) vs 10% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
50% (n=314) vs 18.5% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
82.1% (n=28) vs 17.9% (n=28) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
40.5% (n=215) vs 8.3% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
50% (n=50) vs 6.1% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
67.3% (n=55) vs 17.9% (n=28) Methotrexate @ 24wk7.5 mg
NCT02706873 · Phase 3
36.7% (n=49) vs 6.1% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
19.5% (n=41) vs 10.5% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
22.4% (n=49) vs 14.9% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
7.7% (n=39) vs 10.5% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
42.9% (n=49) vs 14.9% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
32.3% (n=62) vs 10.5% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
34% (n=50) vs 14.9% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
38.8% (n=49) vs 14.9% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
9.8% (n=41) vs 10.5% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 14.9% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
CDAI Low Disease Activity 40.3% (n=221) vs 19% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 23 more results
35.5% (n=169) vs 11.2% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
42% (n=219) vs 19% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
9.8% (n=41) vs 10.5% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 5.3% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
34.1% (n=41) vs 26.3% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
36.7% (n=49) vs 21.3% (n=47) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 10.5% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.7% (n=39) vs 10.5% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
20.5% (n=39) vs 5.3% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.9% (n=39) vs 26.3% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
49% (n=49) vs 21.3% (n=47) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
16.1% (n=62) vs 10.5% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
29% (n=62) vs 10.5% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
46.8% (n=62) vs 5.3% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
37.1% (n=62) vs 26.3% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
40% (n=50) vs 21.3% (n=47) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
2.4% (n=41) vs 10.5% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.2% (n=41) vs 10.5% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
24.4% (n=41) vs 5.3% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 26.3% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
40.8% (n=49) vs 21.3% (n=47) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
Morning Stiffness Duration -85.28 vs -34.27 placebo minutes @ 12wk15 mg
absolute change · minutes
NCT02675426 · Phase 3
show 3 more results
-94.56 vs -53.03 Methotrexate minutes @ 14wk15 mg
NCT02706951 · Phase 3
-85.13 vs -34.27 placebo minutes @ 12wk30 mg
NCT02675426 · Phase 3
-102.34 vs -53.03 Methotrexate minutes @ 14wk30 mg
NCT02706951 · Phase 3
FACIT-Fatigue 7.91 vs 2.96 placebo score @ 12wk15 mg
absolute change · score
NCT02675426 · Phase 3
show 4 more results
3.6 vs 1.81 placebo score @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
7.74 vs 2.96 placebo score @ 12wk30 mg
NCT02675426 · Phase 3
2.66 vs 1.81 placebo score @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.47 vs 1.81 placebo score @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
ACR50 38% (n=221) vs 14.9% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 41 more results
52.1% (n=317) vs 28.3% (n=314) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
60.3% (n=317) vs 33.4% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
66.7% (n=27) vs 21.4% (n=28) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
41.9% (n=217) vs 15.3% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
34.1% (n=164) vs 11.8% (n=169) placebo @ 12wk15 mg
NCT02706847 · Phase 3
40.8% (n=169) vs 8.3% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
65.3% (n=49) vs 16.3% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
43.4% (n=219) vs 14.9% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
56.4% (n=314) vs 28.3% (n=314) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
65.6% (n=314) vs 33.4% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
71.4% (n=28) vs 21.4% (n=28) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
52.1% (n=215) vs 15.3% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
35.8% (n=165) vs 11.8% (n=169) placebo @ 12wk30 mg
NCT02706847 · Phase 3
58% (n=50) vs 16.3% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
60% (n=55) vs 21.4% (n=28) Methotrexate @ 12wk7.5 mg
NCT02706873 · Phase 3
40.8% (n=49) vs 16.3% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
4.9% (n=41) vs 0% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 10.5% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
19.5% (n=41) vs 5.3% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
29.3% (n=41) vs 21.1% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
43.8% (n=48) vs 19.6% (n=46) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 0% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 10.5% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8% (n=39) vs 5.3% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
12.8% (n=39) vs 21.1% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
44.7% (n=47) vs 19.6% (n=46) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
40% (n=55) vs 17% (n=53) placebo @ 12wk*18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 22 Participants as posted
16.1% (n=62) vs 0% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
19.4% (n=62) vs 10.5% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
41.9% (n=62) vs 5.3% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
45.2% (n=62) vs 21.1% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
50% (n=50) vs 19.6% (n=46) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
43.6% (n=55) vs 17% (n=53) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 24 Participants as posted
49% (n=49) vs 19.6% (n=46) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
38.5% (n=52) vs 17% (n=53) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 20 Participants as posted
0% (n=41) vs 0% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.9% (n=41) vs 10.5% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
7.3% (n=41) vs 5.3% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
17.1% (n=41) vs 21.1% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
39.6% (n=48) vs 19.6% (n=46) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
24.1% (n=54) vs 17% (n=53) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 13 Participants as posted
ACR70 20.8% (n=221) vs 5.9% (n=221) placebo @ 12wk15 mg
responder rate · % of participants
NCT02675426 · Phase 3
show 41 more results
32.5% (n=317) vs 14% (n=314) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
44.5% (n=317) vs 18.5% (n=314) Methotrexate @ 24wk15 mg
NCT02706873 · Phase 3
51.9% (n=27) vs 0% (n=28) Methotrexate @ 12wk15 mg
NCT02706873 · Phase 3
22.6% (n=217) vs 2.8% (n=216) Methotrexate @ 14wk15 mg
NCT02706951 · Phase 3
11.6% (n=164) vs 6.5% (n=169) placebo @ 12wk15 mg
NCT02706847 · Phase 3
21.3% (n=169) vs 3.6% (n=169) placebo @ 12wk15 mg
NCT02955212 · Phase 3 · registry result, not featured evidence
34.7% (n=49) vs 2% (n=49) placebo @ 12wk15 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
26.5% (n=219) vs 5.9% (n=221) placebo @ 12wk30 mg
NCT02675426 · Phase 3
36.9% (n=314) vs 14% (n=314) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
49.7% (n=314) vs 18.5% (n=314) Methotrexate @ 24wk30 mg
NCT02706873 · Phase 3
64.3% (n=28) vs 0% (n=28) Methotrexate @ 12wk30 mg
NCT02706873 · Phase 3
33% (n=215) vs 2.8% (n=216) Methotrexate @ 14wk30 mg
NCT02706951 · Phase 3
23% (n=165) vs 6.5% (n=169) placebo @ 12wk30 mg
NCT02706847 · Phase 3
28% (n=50) vs 2% (n=49) placebo @ 12wk30 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
34.5% (n=55) vs 0% (n=28) Methotrexate @ 12wk7.5 mg
NCT02706873 · Phase 3
20.4% (n=49) vs 2% (n=49) placebo @ 12wk7.5 mg
NCT02720523 · Phase 2/3 · registry result, not featured evidence
2.4% (n=41) vs 0% (n=19) placebo @ 2wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.9% (n=41) vs 0% (n=19) placebo @ 4wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
4.9% (n=41) vs 0% (n=19) placebo @ 8wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
14.6% (n=41) vs 15.8% (n=19) placebo @ 12wk60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
25% (n=48) vs 6.5% (n=46) placebo @ 12wk24 mg QD
NCT02066389 · Phase 2 · registry result, not featured evidence
0% (n=39) vs 0% (n=19) placebo @ 2wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 4wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
2.6% (n=39) vs 0% (n=19) placebo @ 8wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
5.1% (n=39) vs 15.8% (n=19) placebo @ 12wk20 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
27.7% (n=47) vs 6.5% (n=46) placebo @ 12wk18 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
21.8% (n=55) vs 3.6% (n=55) placebo @ 12wk*18 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
8.1% (n=62) vs 0% (n=19) placebo @ 2wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
9.7% (n=62) vs 0% (n=19) placebo @ 4wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
17.7% (n=62) vs 0% (n=19) placebo @ 8wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
25.8% (n=62) vs 15.8% (n=19) placebo @ 12wk15 mg/60 mg
NCT03682705 · Phase 2 · registry result, not featured evidence · combination
16% (n=50) vs 6.5% (n=46) placebo @ 12wk12 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
21.8% (n=55) vs 3.6% (n=55) placebo @ 12wk*12 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 12 Participants as posted
30.6% (n=49) vs 6.5% (n=46) placebo @ 12wk6 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
26.9% (n=52) vs 3.6% (n=55) placebo @ 12wk*6 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 14 Participants as posted
0% (n=41) vs 0% (n=19) placebo @ 2wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 4wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
0% (n=41) vs 0% (n=19) placebo @ 8wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
9.8% (n=41) vs 15.8% (n=19) placebo @ 12wk5 mg
NCT03682705 · Phase 2 · registry result, not featured evidence
23.4% (n=47) vs 6.5% (n=46) placebo @ 12wk3 mg BID
NCT02066389 · Phase 2 · registry result, not featured evidence
13% (n=54) vs 3.6% (n=55) placebo @ 12wk*3 mg BID
NCT01960855 · Phase 2 · registry result, not featured evidence · converted to % from 7 Participants as posted
Modified Sharp 0.14 vs 0.67 Methotrexate score @ 24wk15 mg
absolute change · score
NCT02706873 · Phase 3
show 4 more results
0.24 vs 2.64 Methotrexate score @ 24wk15 mg
NCT02706873 · Phase 3
0.07 vs 0.67 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
0.19 vs 2.64 Methotrexate score @ 24wk30 mg
NCT02706873 · Phase 3
0.95 vs 2.64 Methotrexate score @ 24wk7.5 mg
NCT02706873 · Phase 3

+ 18 further endpoints in the CSV export.

The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: upadacitinib's landscape · Zemprocitinib's landscape